Phaseline

Targets › BRDT

BRDT (Bromodomain testis-specific protein): drug programs, companies and trials

4 programs from 4 companies in 11 trials: 7 Phase 1, 3 Phase 3, 1 Phase 2; Oncology, Other, Infectious disease; next expected readout Nov 2026.

Testis-specific chromatin protein that specifically binds histone H4 acetylated at 'Lys-5' and 'Lys-8' (H4K5ac and H4K8ac, respectively) and plays a key role in spermatogenesis. Required in late pachytene spermatocytes: plays a role in meiotic and post-meiotic cells by binding to acetylated histones at the promoter of specific meiotic and post-meiotic genes, facilitating their activation at the appropriate time. (UniProt, Q58F21)

Open in Phaseline: the race on BRDT, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NovartisPelabresib
Bromodomain and extra-terminal motif (BET) inhibitor
BRD2, BRD4, BRDT, BRD3Phase 3Hematologic Malignancy; Myelofibrosis; Primary Myelofibrosis (PMF); Healthy Participants …Nov 2026
ResverlogixApabetalone (RVX000222)
Bromodomain and extra-terminal motif (BET) inhibitor
BRD2, BRD4, BRDT, BRD3Phase 2Post-Acute COVID-19 Syndrome–
Chia Tai Tianqing Pharmaceutical GroupTQB3617 Capsules
Bromodomain and Extra-Terminal (BET) inhibitor
BRD2, BRD3, BRD4, BRDTPhase 1MyelofibrosisDec 2026
Bristol-Myers SquibbEzobresib (BMS-986158)
Bromodomain and extra-terminal motif (BET) inhibitor
BRD2, BRD4, BRDT, BRD3Phase 1Multiple Myeloma; MyelofibrosisAug 2028

Conditions

Myelofibrosis (3) Primary Myelofibrosis (PMF) (2) Hematologic Malignancy (1) Healthy Participants (1) Advanced Malignancies (1) Advanced Malignancies and Hepatic Impairment (1) Multiple Myeloma (1) Post-Acute COVID-19 Syndrome (1)

Modalities

small molecule (4)

Companies

Novartis (1) Chia Tai Tianqing Pharmaceutical Group (1) Bristol-Myers Squibb (1) Resverlogix (1)

Related targets

BRD2 (4) BRD4 (4) BRD3 (4)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.